Researchers slash time needed to produce CAR T cells for cancer patients in need

By The Science Advisory Board staff writers

October 25, 2022 -- Researchers at University Hospitals (UH) Seidman Cancer Center and their collaborators have streamlined the production of CAR T cells, a mainstay of modern immunotherapy treatment for certain cancers.

The team is among the U.S.'s first to test this manufacturing approach, according to an October 21 statement from UH.

CAR T-cell therapy allows oncologists to identify markers on the surfaces of cancer cells, then reverse-engineer a person's own normal T cells into CAR T cells that seek out the marked cells and destroy the cancer.

An estimated 25% of cancer patients slated to receive CAR T-cell therapy suffer disease progression before they can receive treatment, making quicker therapy a vital concern. Commercial supplier deliveries may currently take three weeks. The new process could potentially reduce CAR T-cell delivery to 24 hours. Further, rapidly manufactured CAR T cells appear more potent than traditionally manufactured cells.

In November 2022, the researchers will launch a phase I clinical trial of the rapidly manufactured CAR T cells in adults with relapsed or refractory non-Hodgkin's lymphoma. If successful, they plan to expand testing to patients with other cancers.

The research team's goal is to make the manufacturing process simple, inexpensive, and accessible to hospitals without advanced equipment worldwide. They are optimistic about the difference the new process could make for cancer patients.

"This will help the sickest among our lymphoma patients, who often don't have the time to wait for the lengthy manufacturing process in order to receive lifesaving CAR T therapy," UH hematology chief Dr. Koen van Besien, PhD, said in a statement.

Low phosphate levels linked with CAR T neurological toxicity
Patients with hypophosphatemia had higher incidences and more severe neurological side effects on chimeric antigen receptor (CAR) T-cell therapy than...
New type of CAR T cells provide on-off switch to improve cell therapy safety, efficiency
Researchers at Boston University have created on and off switches for chimeric antigen receptor (CAR) T cells, enabling them to control the activity of...
CRISPR reveals way to enhance the function, persistence of CAR T-cell therapies
The use of CRISPR knockout screens have uncovered a new regulator of immunity that could enhance the function and persistence of anticancer T-cell therapies,...
New technique could enable production of generic CAR T cells at scale
A Boston Children’s Hospital lab has developed a new method that could make chimeric antigen receptor (CAR) T-cell therapy more widely available using...
Mustang Bio focuses on CD20 antigen for CAR T-cell therapy
Biopharmaceutical company Mustang Bio is focused on a CD20-targeted autologous chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma,...
CAR T-cells show preliminary efficacy, safety as solid-tumor treatment
Researchers presented phase I/II preliminary clinical trial data demonstrating the safety and efficacy of a new CAR T-cell therapy that can be used as...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter